BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neumann PJ, Cohen JT, Kim DD, Ollendorf DA. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic: Study reviews alternative pricing strategies (cost-recovery models, monetary prizes, advanced market commitments) for COVID-19 drugs, vaccines, and diagnostics. Health Affairs 2021;40:53-61. [DOI: 10.1377/hlthaff.2020.01548] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Yayehrad AT, Siraj EA, Yimenu DK, Ambaye AS, Derseh MT, Tamene AA, Yayeh TG. Multidisciplinary Effort and Integrative Preparedness: A Lesson for the Foreseen Multivariate COVID-19 Pandemic Flare-Up. J Multidiscip Healthc 2021;14:2905-21. [PMID: 34703243 DOI: 10.2147/JMDH.S332049] [Reference Citation Analysis]
2 Gandjour A. Value-based pricing of a COVID-19 vaccine. Q Rev Econ Finance 2022;84:1-8. [PMID: 34975265 DOI: 10.1016/j.qref.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Neumann PJ, Podolsky MI, Basu A, Ollendorf DA, Cohen JT. Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications. Value Health 2022;25:59-68. [PMID: 35031100 DOI: 10.1016/j.jval.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Blakely T, Thompson J, Bablani L, Andersen P, Ait Ouakrim D, Carvalho N, Abraham P, Boujaoude M, Katar A, Akpan E, Wilson N, Stevenson M. Association of Simulated COVID-19 Policy Responses for Social Restrictions and Lockdowns With Health-Adjusted Life-Years and Costs in Victoria, Australia. JAMA Health Forum 2021;2:e211749. [DOI: 10.1001/jamahealthforum.2021.1749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Painter C, Isaranuwatchai W, Prawjaeng J, Wee HL, Chua BWB, Huynh VA, Lou J, Goh FT, Luangasanatip N, Pan-Ngum W, Yi W, Clapham H, Teerawattananon Y. Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines. Appl Health Econ Health Policy 2021;19:463-72. [PMID: 34235643 DOI: 10.1007/s40258-021-00661-5] [Reference Citation Analysis]
6 Vassall A, Sweeney S, Barasa E, Prinja S, Keogh-brown MR, Tarp Jensen H, Smith R, Baltussen R, M Eggo R, Jit M. Integrating economic and health evidence to inform Covid-19 policy in low- and middle- income countries. Wellcome Open Res 2020;5:272. [DOI: 10.12688/wellcomeopenres.16380.2] [Reference Citation Analysis]
7 Neumann PJ, Ollendorf DA, Cohen JT. Value-based drug pricing in the Biden era: Opportunities and prospects. Health Serv Res 2021. [PMID: 34085289 DOI: 10.1111/1475-6773.13686] [Reference Citation Analysis]
8 Chua BWB, Huynh VA, Lou J, Goh FT, Clapham H, Teerawattananon Y, Wee HL. Protocol for the economic evaluation of COVID-19 pandemic response policies. BMJ Open 2021;11:e051503. [PMID: 34521677 DOI: 10.1136/bmjopen-2021-051503] [Reference Citation Analysis]
9 Whittington MD, Pearson SD, Rind DM, Campbell JD. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19. Value in Health 2022. [DOI: 10.1016/j.jval.2021.11.1378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Towse A, Chalkidou K, Firth I, Kettler H, Silverman R. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Value Health 2021;24:625-31. [PMID: 33933230 DOI: 10.1016/j.jval.2020.12.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li M, Ren J, Si X, Sun Z, Wang P, Zhang X, Liu K, Wei B. The global mRNA vaccine patent landscape. Hum Vaccin Immunother 2022;:2095837. [PMID: 35797353 DOI: 10.1080/21645515.2022.2095837] [Reference Citation Analysis]
12 Qiu T, Wang Y, Liang S, Han R, Toumi M. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. Drug Discov Today 2021:S1359-6446(21)00207-5. [PMID: 33892148 DOI: 10.1016/j.drudis.2021.04.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Yuasa A, Yonemoto N, LoPresti M, Ikeda S. Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2021;21:235-45. [PMID: 33593223 DOI: 10.1080/14737167.2021.1881484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yin F, Ji M, Yang Z, Wu Z, Xia X, Xing T, She Y, Hu Z. Exploring the determinants of global vaccination campaigns to combat COVID-19. Humanit Soc Sci Commun 2022;9. [DOI: 10.1057/s41599-022-01106-7] [Reference Citation Analysis]
15 Asukai Y, Briggs A, Garrison LP, Geisler BP, Neumann PJ, Ollendorf DA. Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. Pharmacoeconomics 2021;39:1201-8. [PMID: 34557996 DOI: 10.1007/s40273-021-01088-5] [Reference Citation Analysis]
16 Machado BAS, Hodel KVS, Fonseca LMDS, Mascarenhas LAB, Andrade LPCDS, Rocha VPC, Soares MBP, Berglund P, Duthie MS, Reed SG, Badaró R. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines (Basel) 2021;9:1345. [PMID: 34835276 DOI: 10.3390/vaccines9111345] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]